Hedge fund could derail McKesson's $8.3bn Celesio buyout
This article was originally published in Scrip
The German pharmaceutical distributor Celesio reported on 26 November that a hedge fund run by Elliott Asset Management has increased its stock ownership, giving it control of 25.16% of the company's shareholder voting rights. That may be enough to derail McKesson's $8.3bn acquisition of Celesio.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.